1. Home
  2. STXS vs ELDN Comparison

STXS vs ELDN Comparison

Compare STXS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STXS
  • ELDN
  • Stock Information
  • Founded
  • STXS 1990
  • ELDN 2004
  • Country
  • STXS United States
  • ELDN United States
  • Employees
  • STXS N/A
  • ELDN N/A
  • Industry
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ELDN Biotechnology: Pharmaceutical Preparations
  • Sector
  • STXS Health Care
  • ELDN Health Care
  • Exchange
  • STXS Nasdaq
  • ELDN Nasdaq
  • Market Cap
  • STXS 173.5M
  • ELDN 140.3M
  • IPO Year
  • STXS 2004
  • ELDN N/A
  • Fundamental
  • Price
  • STXS $2.10
  • ELDN $4.07
  • Analyst Decision
  • STXS Strong Buy
  • ELDN Strong Buy
  • Analyst Count
  • STXS 2
  • ELDN 1
  • Target Price
  • STXS $4.50
  • ELDN $16.00
  • AVG Volume (30 Days)
  • STXS 332.6K
  • ELDN 1.0M
  • Earning Date
  • STXS 11-11-2024
  • ELDN 11-12-2024
  • Dividend Yield
  • STXS N/A
  • ELDN N/A
  • EPS Growth
  • STXS N/A
  • ELDN N/A
  • EPS
  • STXS N/A
  • ELDN N/A
  • Revenue
  • STXS $25,143,000.00
  • ELDN N/A
  • Revenue This Year
  • STXS $1.16
  • ELDN N/A
  • Revenue Next Year
  • STXS $55.65
  • ELDN N/A
  • P/E Ratio
  • STXS N/A
  • ELDN N/A
  • Revenue Growth
  • STXS N/A
  • ELDN N/A
  • 52 Week Low
  • STXS $1.51
  • ELDN $1.11
  • 52 Week High
  • STXS $3.29
  • ELDN $5.54
  • Technical
  • Relative Strength Index (RSI)
  • STXS 53.19
  • ELDN 51.95
  • Support Level
  • STXS $1.96
  • ELDN $3.76
  • Resistance Level
  • STXS $2.12
  • ELDN $4.17
  • Average True Range (ATR)
  • STXS 0.12
  • ELDN 0.39
  • MACD
  • STXS 0.01
  • ELDN -0.15
  • Stochastic Oscillator
  • STXS 50.00
  • ELDN 18.45

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: